UpdatesPress Release
Windlas Biotech achieved record FY26 revenue of Rs 904 Cr, up 19% YoY, fueled by 20% CDMO growth.
Windlas Biotech LimitedWINDLAS · Filed with the exchange
Adjusted PAT rose 31% to Rs 83 Cr.
With Rs 251 Cr net liquidity and debt-free status, the company saw strong cash generation and Plant-6 nearing commercialization.
No comments yet. Be the first.